On May 17, 2023 Biomissile, a biotech company developing fully human domain antibody (UDABTM) and multi-specific antibody (UDAB-MTM) reported the successful completion of a ￥200M (CNY) Series B fundraising (Press release, Biomissile, MAY 17, 2023, View Source;article_category_id=1&article_id=16 [SID1234644276]). Proceeds from the financing will be used to advance the company’s UDAB-MTM based therapeutic pipeline, and further extend its scientific and technical leadership. Series B financing was led by Kequan Fund, along with continued support by existing investor, Fosun Health Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The news in Chinese can be found here: View Source